Canada markets open in 7 hours 38 minutes

QIAGEN N.V. (QGEN)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
48.48-0.18 (-0.37%)
At close: 04:00PM EST
49.00 +0.52 (+1.07%)
After hours: 04:07PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close48.66
Open48.42
Bid0.00 x 1200
Ask0.00 x 900
Day's Range47.82 - 48.82
52 Week Range45.58 - 59.00
Volume833,137
Avg. Volume819,332
Market Cap11.021B
Beta (5Y Monthly)0.22
PE Ratio (TTM)19.00
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • Business Wire

    QIAGEN expands QIAstat-Dx syndromic testing menu and announces launch plans for new QIAstat-Dx Rise higher-throughput version

    HILDEN, Germany & GERMANTOWN, Maryland, January 10, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced important enhancements in the commercialization of its QIAstat-Dx syndromic testing solution – which enables laboratories and hospitals worldwide to test patients for multiple pathogens from one sample – with new tests and the launch of a higher-throughput version that includes a new level of walk-away efficiency through the new QIAstat-Dx Smart Drawer.

  • Business Wire

    QIAGEN Strengthens Growing Portfolio of Applications for Its Digital PCR Platform QIAcuity With New Collaborations

    HILDEN, Germany & GERMANTOWN, Md., January 07, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to the growing number of applications for QIAcuity, its ultrasensitive digital PCR (dPCR) platform that has set new standards by using so-called nanoplates to process samples in two hours rather than the five hours required by other systems.

  • Business Wire

    QIAGEN Expands QuantiFERON Portfolio in the Fight Against TB

    HILDEN, Germany & GERMANTOWN, Md., January 06, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced important expansion initiatives for its QuantiFERON franchise, building on its status as the gold standard for detection of tuberculosis, while developing new applications for this technology designed to detect potentially deadly latent diseases.